BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao D, Zhu GY, Lu Y, Yang A, Chen D, Huang HJ, Peng SX, Chen LW, Li YW. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Biomed Pharmacother 2020;129:110462. [PMID: 32768952 DOI: 10.1016/j.biopha.2020.110462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Vachetta VS, Marder M, Troncoso MF, Elola MT. Opportunities, obstacles and current challenges of flavonoids for luminal and triple-negative breast cancer therapy. European Journal of Medicinal Chemistry Reports 2022;6:100077. [DOI: 10.1016/j.ejmcr.2022.100077] [Reference Citation Analysis]
2 Cao D, Chen D, Xia J, Wang W, Zhu G, Chen L, Zhang C, Tan B, Li H, Li Y. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation. Biomedicine & Pharmacotherapy 2022;155:113705. [DOI: 10.1016/j.biopha.2022.113705] [Reference Citation Analysis]
3 Singh Tuli H, Rath P, Chauhan A, Sak K, Aggarwal D, Choudhary R, Sharma U, Vashishth K, Sharma S, Kumar M, Yadav V, Singh T, Yerer MB, Haque S. Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives. Cancers 2022;14:5373. [DOI: 10.3390/cancers14215373] [Reference Citation Analysis]
4 Zheng Z, Zhang L, Hou X. Potential roles and molecular mechanisms of phytochemicals against cancer. Food Funct 2022;13:9208-25. [PMID: 36047380 DOI: 10.1039/d2fo01663j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Lu M, Lan X, Wu X, Fang X, Zhang Y, Luo H, Gao W, Wu D. Salvia miltiorrhiza in cancer: Potential role in regulating MicroRNAs and epigenetic enzymes. Front Pharmacol 2022;13:1008222. [DOI: 10.3389/fphar.2022.1008222] [Reference Citation Analysis]
6 Zhao Y, Li X, Wang F, Huang S, Du H, Li S, Chen J. Network Pharmacology and Experimental Verification Strategies to Illustrate the Mechanism of Jian-Pi-Yi-Shen Formula in Suppressing Epithelial-Mesenchymal Transition. Front Pharmacol 2022;13:873023. [PMID: 35656312 DOI: 10.3389/fphar.2022.873023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Catalano A, Iacopetta D, Ceramella J, Mariconda A, Rosano C, Scumaci D, Saturnino C, Longo P, Sinicropi MS. New Achievements for the Treatment of Triple-Negative Breast Cancer. Applied Sciences 2022;12:5554. [DOI: 10.3390/app12115554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Akrida I, Bravou V, Papadaki H. The deadly cross-talk between Hippo pathway and epithelial–mesenchymal transition (EMT) in cancer. Mol Biol Rep. [DOI: 10.1007/s11033-022-07590-z] [Reference Citation Analysis]
9 Tian H, Shi H, Yu J, Ge S, Ruan J. Biophysics Role and Biomimetic Culture Systems of ECM Stiffness in Cancer EMT. Global Challenges. [DOI: 10.1002/gch2.202100094] [Reference Citation Analysis]
10 Moral R, Escrich E. Influence of Olive Oil and Its Components on Breast Cancer: Molecular Mechanisms. Molecules 2022;27:477. [PMID: 35056792 DOI: 10.3390/molecules27020477] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
11 Lipovka Y, Alday E, Hernandez J, Velazquez C. Molecular Mechanisms of Biologically Active Compounds from Propolis in Breast Cancer: State of the Art and Future Directions. Food Reviews International. [DOI: 10.1080/87559129.2021.2003380] [Reference Citation Analysis]
12 Li Y, Wang K, Chen Y, Cai J, Qin X, Lu A, Guan D, Qin G, Chen W. A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast Cancer. Front Pharmacol 2021;12:723147. [PMID: 34899291 DOI: 10.3389/fphar.2021.723147] [Reference Citation Analysis]
13 Meerson A, Khatib S, Mahajna J. Natural Products Targeting Cancer Stem Cells for Augmenting Cancer Therapeutics. Int J Mol Sci 2021;22:13044. [PMID: 34884848 DOI: 10.3390/ijms222313044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
14 Deldar Abad Paskeh M, Asadi S, Zabolian A, Saleki H, Khoshbakht MA, Sabet S, Naghdi MJ, Hashemi M, Hushmandi K, Ashrafizadeh M, Mirzaei S, Zarrabi A, Sethi G. Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies. Int J Mol Sci 2021;22:11669. [PMID: 34769099 DOI: 10.3390/ijms222111669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
15 Yeh CF, Chou C, Yang KC. Mechanotransduction in fibrosis: Mechanisms and treatment targets. Curr Top Membr 2021;87:279-314. [PMID: 34696888 DOI: 10.1016/bs.ctm.2021.07.004] [Reference Citation Analysis]
16 Zuo W, Liu N, Zeng Y, Xiao Z, Wu K, Yang F, Li B, Song Q, Xiao Y, Liu Q. Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway. Front Pharmacol 2021;12:663551. [PMID: 33935785 DOI: 10.3389/fphar.2021.663551] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
17 Kalhori MR, Khodayari H, Khodayari S, Vesovic M, Jackson G, Farzaei MH, Bishayee A. Regulation of Long Non-Coding RNAs by Plant Secondary Metabolites: A Novel Anticancer Therapeutic Approach. Cancers (Basel) 2021;13:1274. [PMID: 33805687 DOI: 10.3390/cancers13061274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
18 Xie S, Wu Z, Qi Y, Wu B, Zhu X. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother 2021;138:111450. [PMID: 33690088 DOI: 10.1016/j.biopha.2021.111450] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
19 Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel) 2021;10:349. [PMID: 33652780 DOI: 10.3390/antiox10030349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]
20 Kawamoto R, Nakano N, Ishikawa H, Tashiro E, Nagano W, Sano K, Irie M, Ikuta M, Kishi F, Nakane T, Naito M, Itoh S. Narciclasine is a novel YAP inhibitor that disturbs interaction between YAP and TEAD4. BBA Advances 2021;1:100008. [DOI: 10.1016/j.bbadva.2021.100008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Siddiqui N, Abidin L, Nisar N, Ahmad I, Siddiqui AN. Flavonoids Targeting Cancer Stem Cells: A Paradigm to Anticancer Efficacy. Polyphenols-based Nanotherapeutics for Cancer Management 2021. [DOI: 10.1007/978-981-16-4935-6_7] [Reference Citation Analysis]
22 Xu X, Liu M, Yang Y, Wei C, Zhang X, Song H, Wang Y, Duan X. VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway. Oncol Rep 2021;45:975-86. [PMID: 33650675 DOI: 10.3892/or.2020.7916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhao W, Wang M, Cai M, Zhang C, Qiu Y, Wang X, Zhang T, Zhou H, Wang J, Zhao W, Shao R. Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancer. Biomed Pharmacother 2021;133:110956. [PMID: 33189066 DOI: 10.1016/j.biopha.2020.110956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]